Stipple Bio Partners With Eli Lilly on Cancer Drugs
The private biotech company's collaboration with Lilly spans multiple targets and therapeutic modalities, with milestone payments of up to $5.9 billion.
Updated on Nov. 16, 2026 in Biotech

Cambridge, Massachusetts-based Stipple Bio, Inc. entered a multi-target, multi-modality strategic research collaboration and license agreement with Eli Lilly and Company. Lilly receives exclusive worldwide rights to develop and commercialize products arising from the collaboration.
Why it matters
The deal pairs Stipple Bio's Pointillist Platform, which identifies tumor-specific cell surface epitope binders, with Lilly's proprietary oncology technologies. The partners expect the approach to increase efficacy and reduce on-target, off-tumor toxicity of therapies.
Stipple Bio's Pointillist Platform is designed to identify tumor-specific cell surface epitope binders for combination with Lilly's oncology technologies across multiple modalities. The upfront payment, equity stake size and royalty rates were not disclosed.
The players
Stipple Bio, Inc.
A private biotechnology company headquartered in Cambridge, Massachusetts, named to the 2026 Endpoints 11 list of biotech's most promising private companies.
Eli Lilly and Company
A large U.S. pharmaceutical company that has built a substantial oncology research portfolio and is partnering here to develop and commercialize products from the collaboration.
The details
Under the agreement, Stipple Bio will use its platform to discover novel binders, which Lilly will combine with its own technologies to advance compounds with high therapeutic index. Stipple Bio is also eligible for tiered royalties if Lilly commercializes therapies from the collaboration.
Timeline
November 16, 2026: Stipple Bio announced the Lilly collaboration and license agreement.
Early 2027: Stipple Bio plans to initiate a Phase 1 clinical trial for its first-in-class ADC STP-100 in solid tumors, including pancreatic cancer.
The Tech Race
The deal reflects the broader pharmaceutical push into antibody-drug conjugates, a modality that combines targeted antibodies with cytotoxic payloads to attack tumors while sparing healthy tissue. Stipple Bio's platform aims to improve on earlier ADC designs by reducing toxicity to healthy tissue.
If the planned trials succeed, targeted ADC therapies could offer cancer patients treatments with fewer side effects from damage to healthy tissue. Any approved products are still years away and no timeline for availability has been set.
The takeaway
Pharmaceutical partnerships with early-stage private biotechs are becoming a common route to new cancer drug candidates. Readers tracking this space should watch whether the planned 2027 Phase 1 trial produces clinical data.
What happens next
Stipple Bio plans to initiate a Phase 1 clinical trial for STP-100 in early 2027.
Further reading
Explore more biotech news for related developments in cancer drug development.




